Renal

Clear Cell

Non-Clear Cell

Localized

Metastatic / Locally Advanced

No Prior Systemic Therapy

Prior Systemic Therapy

IRB# 22759
S1931: Phase III Trial of Immuno-therapy Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE)

IRB# 22193
MK6482-012: An Open label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First Line Treatment in Participants with Advanced cCRCC

IRB# 19991
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)

IRB# 24768
No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

IRB# 24768
Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

IRB# 243619
NKT2152-101: A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, An Orally Administered HIF2α Inhibitor, To Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma

Nephrectomy Candidate

Papillary Renal Carcinoma

TBD

TBD

TBD

TBD

TBD

TBD

TBD

T1b or greater (has not spread beyond the kidney)

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

12-OCT-2022